Novo Nordisk's US Filing for Hemophilia Drug Slips as Analysts Turn Cautious
Published on 10/06/2026 at 20:20 | Editorial boerse-global.de
Novo Nordisk has run into another regulatory speed bump in the United States, and the market is not taking the news lightly. Shares of the Danish drugmaker fell 1.8% to EUR 32.85 in European trading on Tuesday after the US Food and Drug Administration extended its review of Denecimig, an experimental treatment for hemophilia A.
The delay stems from ongoing remediation work at an unnamed manufacturing site, and the agency has not yet set a new decision date. That matters because Novo Nordisk had been counting on a verdict in the third quarter of 2026 for a filing submitted in September 2025. The company stressed that the holdup is not tied to safety or efficacy concerns and that its financial outlook for 2026 stands unchanged. Even so, the episode underscores how manufacturing compliance issues can throttle the pace of new product launches.
A Pipeline Bet That Cannot Afford to Slip
The bigger question for investors is whether Novo Nordisk can pivot away from its heavy reliance on GLP-1 drugs toward a more diversified pipeline. Management still aims to bring Denecimig to the US market in the first half of 2027 if cleared, but every month of delay erodes an advantage in the competitive niche for rare blood disorders.
Meanwhile, the company's core growth engine is losing steam. Reports of declining reimbursement from US insurers and employers are piling up, and new prescription growth is moderating. With rivals such as Eli Lilly advancing compounds like retatrutide and Roche pushing its own candidates, Novo Nordisk needs fresh pillars for its portfolio. Market confidence now hinges largely on how quickly the Danes can resolve their production quality issues.
Buybacks and a European Opening
There is a brighter side to the story. Novo Nordisk remains highly profitable and is actively defending its share price. Under a twelve-month buyback program worth up to DKK 15 billion, the company had repurchased B-shares for DKK 10.247 billion between February and early October 2026. That steady removal of freely tradable stock offers a counterweight to recent selling.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Europe, moreover, has not closed its door to Denecimig. The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion in mid-September recommending approval for adults and children with hemophilia A. Should the European Commission follow that recommendation, the therapy could launch in its home region on schedule. Novo Nordisk is already running patient-preference surveys in Germany to fine-tune its market positioning.
A Stock Under Pressure
The bear case rests on the shares' persistent weakness, with a year-to-date decline of 25%. If inspections and manufacturing shortcomings at the plants become a recurring theme, further delays beyond Denecimig are plausible. A regulatory blockade in the world's most important pharmaceutical market would do lasting damage to institutional confidence.
Price and innovation competition add to the strain. Eli Lilly has posted markedly higher growth rates in recent quarters, and industry data point to a normalizing market. Roughly 40% of patients on several GLP-1 treatments struggle with side effects such as nausea, leading to discontinuations. If competitors bring better-tolerated drugs to market faster, Novo Nordisk risks meaningful share losses.
Fresh Data, Mixed Signals
Against that backdrop, Novo Nordisk released a pair of studies that bolster its clinical story. On September 29, it published a retrospective real-world analysis of 636,525 adults with type-2 diabetes. Dose escalation of semaglutide was associated with a 6% lower risk of major cardiovascular events than switching to tirzepatide. The company acknowledges the analysis cannot establish causality on methodological grounds, but the statistical comparison offers tangible arguments for clinical practice. In the battle for market share, the finding strengthens Novo Nordisk's hand against alternative treatment options, particularly given the role cardiovascular comorbidities play in therapy selection for type-2 diabetics.
A day later, Novo Nordisk presented data from the OCTANE study. Patients who switched from injectable therapies to the oral form of Wegovy lost an average of 4.1% of their body weight over three months. The research draws on treatment data from the telemedicine platform Ro. Oral formulations are a key strategic lever for the company, designed to lower barriers to injection therapy and reach new patient groups while broadening the therapeutic range of its product family.
CFRA Turns Bearish
Sentiment on the financial markets remains subdued despite the study results. On September 22, research firm CFRA downgraded Novo Nordisk's American depositary receipts from Hold to Sell, setting a price target of $38.00. The analysts cited an unfavorable risk-reward profile and mounting competitive pressure. CFRA also pointed to muted earnings growth over the coming years, though it flagged Wegovy tablets as an opportunity in the near term. Investors had already grown sensitive to the company's long-term prospects; shares fell noticeably after the preceding capital markets day as management's growth targets met with skepticism.
In premarket trading on Tuesday, the stock held steady at EUR 33.69, up 0.7%, though it remains down 23% for the year so far.
What Washington and Brussels Decide Next
The path forward now depends on how fast management clears its manufacturing requirements. Until the plant remediation is officially complete, the US approval for Denecimig stays in limbo. A successful re-inspection in the coming months and a resumption of the review would likely ease selling pressure considerably. The next concrete catalyst is formal authorization from the European Commission, which traditionally follows a positive CHMP vote. A green light in Brussels would kick off the European launch and demonstrate that the drug is clinically convincing. For now, Novo Nordisk remains a test case: only when US regulatory hurdles fall will its planned expansion beyond diabetes rest on solid ground.
Ad
Novo Nordisk Stock: New Analysis - 6 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
